Expanding the Analytical Toolkit for siRNA Development to Build Phase- Appropriate CMC Control Strategies

• Assessing which analytical tools are most critical for characterizing siRNA quality attributes to support confident progression from early development into the clinic
• Exploring how impurity, conjugation, and structural complexity considerations are shaping analytical strategy as siRNA programs become more advanced and diverse
• Sharing how analytical development, QC, and CMC teams can align on phase appropriate expectations so resources are focused on what matters most at each stage of development

Speakers: